Literature DB >> 19263054

[Procedural guidelines. Good tissue practice for cornea banks].

J Schroeter1, P Maier, J Bednarz, K Blüthner, M Quenzel, A Pruss, T Reinhard.   

Abstract

A cornea bank must have an organizational structure in which responsibility and authority to issue directives are clearly defined. It must also use a documented quality management system on the basis of good practice procedures which is maintained to the current standards. The personnel of a cornea bank must be present in sufficient numbers and be suitably qualified. A cornea bank must be in possession of appropriate facilities which are suitable for the main purpose of conservation of donor corneas. All equipment must be designed and maintained corresponding to the intended purpose. Deviations from the stipulated quality and safety standards must give rise to documented investigations which include decisions on options for correctional and preventive measures. Acquisition of donors and tissue sampling must be strictly controlled and documented. This also applies to entry of donor tissue in the cornea bank. During conservation a microscopic examination of the endothelial cell layer must be carried out at least once. Measures must be taken to keep the risk of contamination as low as possible. Donor corneal tissue can only be released if defined criteria are fulfilled. Any suspicion of severe undesired reactions and events for the recipient of a corneal transplant must be registered with the authorities. The activities of a cornea bank must maintain and adapt the state-of-the-art with respect to scientific progress.

Entities:  

Mesh:

Year:  2009        PMID: 19263054     DOI: 10.1007/s00347-008-1913-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  8 in total

1.  [The 2009 performance report of the German cornea banks].

Authors:  N Schrage; T Reinhard; B Seitz; M Hermel; D Böhringer; H Reinshagen
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

2.  Impact of temporary hyperthermia on corneal endothelial cell survival during organ culture preservation.

Authors:  Jan Schroeter; Alfredo Ruggeri; Hagen Thieme; Christian Meltendorf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-10       Impact factor: 3.117

3.  Comparison of in situ Corneoscleral Disc Excision versus Whole Globe Enucleation in Cornea Donors Regarding Microbial Contamination in Organ Culture Medium - a Prospective Monocentric Study over 9 Years.

Authors:  Jan Schroeter; Ina Wilkemeyer; Frithjof Herrlinger; Axel Pruss
Journal:  Transfus Med Hemother       Date:  2012-11-21       Impact factor: 3.747

4.  [Results of an internet-based survey amongst members of the German Ophthalmological Society concerning postmortem cornea donation].

Authors:  C E Uhlig; J Promesberger; G Hirschfeld; R Koch; T Reinhard; B Seitz
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

5.  Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Authors:  Ingo Schmack; Seda Ballikaya; Brigitte Erber; Irina Voehringer; Ulrich Burkhardt; Gerd U Auffarth; Paul Schnitzler
Journal:  Transfus Med Hemother       Date:  2019-09-24       Impact factor: 3.747

6.  Comparison of Total Immunoglobulin G in Ante- and Postmortem Blood Samples from Tissue Donors.

Authors:  Gudrun Larscheid; Tino Schulz; Hermann Herbst; Tina Trögel; Sascha Eulert; Axel Pruß; Jan Schroeter
Journal:  Transfus Med Hemother       Date:  2021-01-05       Impact factor: 3.747

7.  Cornea Procurement and Processing up to 72 Hours: No Risk for Cornea Transplant Quality.

Authors:  Nicola Hofmann; Ilka Wittmershaus; Anna-Katharina Salz; Martin Börgel
Journal:  Transfus Med Hemother       Date:  2020-10-08       Impact factor: 3.747

8.  Validation of Microbiological Testing of Tissue Preparations with Different Incubation Temperatures.

Authors:  Frithjof Herrlinger; Tino Schulz; Axel Pruß; Eva Schulz
Journal:  Transfus Med Hemother       Date:  2020-12-16       Impact factor: 3.747

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.